Synthesis of Potent and Selective Inhibitors Against the Proliferation of Human Coronary Artery Smooth Muscle Cells.
✍ Scribed by Haruhisa Ogita; Yoshiaki Isobe; Haruo Takaku; Rena Sekine; Yuso Goto; Satoru Misawa; Hideya Hayashi
- Publisher
- John Wiley and Sons
- Year
- 2003
- Weight
- 98 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0931-7597
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Proteoglycans accumulate in lesions of atherosclerosis but little is known as to which factors regulate the synthesis of these molecules. Interleukin‐1β (IL‐1β) is a cytokine involved in vascular lesion development but it is not clear whether it has specific effects on proteoglycan synt
## Abstract Platelet‐derived growth factor (PDGF) has been implicated in the pathogenesis of arterial atherosclerosis and venous neointimal hyperplasia. We examined the effects of PDGF isoforms on smooth muscle cells (SMCs) from arterial and venous origins in order to further understand the differe
## Abstract Platelet‐derived growth factor (PDGF) has been implicated in smooth muscle cell (SMC) proliferation, a key event in the development of myointimal hyperplasia in vascular grafts. Recent evidence suggests that the PDGF receptor (PDGFR) tyrosine kinase inhibitor, imatinib, can prevent arte
## Abstract Versican is an extracellular matrix proteoglycan produced by many cells. Although versican is generally known as a large chondroitin sulfate proteoglycan (CSPG), the smallest splice variant, V3, consists only of the amino‐ and carboxy‐terminal globular domains and is therefore predicted
Hormone replacement therapy (HRT) for post-menopausal symptoms in diabetes is associated with increased risk of coronary heart disease and stroke. Therefore, there is a need for new HRT with no adverse effects on diabetic post-menopausal women. We developed peptides as potential estrogen mimetic com